Ceranova (IT)
{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~8 mi. (Pavia, Italy, +383 more cities)
facility
Fondazione Salvatore Maugeri, +1 more facility
biomarker
ER Negative, +2 more biomarkers
condition
Breast Carcinoma
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~8 mi. (Pavia, Italy, +141 more cities)
facility
GSK Investigational Site
condition
Multiple Myeloma
drug
belantamab mafodotin
drug type
chemotherapy, +1 more type
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
city
~8 mi. (Pavia, Italy, +74 more cities)
facility
GSK Investigational Site
condition
Multiple Myeloma
drug
belantamab mafodotin, +3 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~13 mi. (Rozzano, Italy, +89 more cities)
facility
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1114)
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~13 mi. (Rozzano, Italy, +226 more cities)
facility
Istituto Clinico Humanitas Research Hospital ( Site 0452)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~13 mi. (Rozzano, Italy, +153 more cities)
facility
IRCSS Istituto Clinico Humanitas - U.O. Oncologia Medica
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
drug type
immunotherapy
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~13 mi. (Rozzano, Italy, +158 more cities)
facility
Istituto Clinico Humanitas Research Hospital ( Site 1000)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
city
~13 mi. (Rozzano, Italy, +179 more cities)
facility
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
condition
Esophageal Squamous Cell Carcinoma
drug
atezolizumab, +1 more drug
drug type
immunotherapy